Molecular Testing Guideline for Selection of Lung Cancer Patients - Revision
This content was created in 2018, but has been reviewed and approved by the Training & Education Committee as useful, accurate, and relevant. Please note that in the time since this material was posted, there may have been additional developments, advancements, and/or more current publications in this field.
AMP Education is constantly updating our educational offerings, and will remove or replace content that is no longer accurate. Please be sure to use the search function to find related or updated material available in our catalogue at educate.amp.org. The Training and Education Committee works with AMP Education Programs to bring you the most up-to-date and cutting-edge information on molecular pathology research, applications, and training.
Neal Lindeman, MD
Anna Yemelyanova, MD
This webinar is a recorded presentation of a live broadcast and includes the presentation, handout, and the audience QA.
The advent of targeted therapies based on predictive biomarkers has dramatically altered the role of the molecular pathologist in lung cancer patient care. This webinar reviews the new recommendations published in the revised 2018 CAP/IASLC/AMP lung cancer predictive biomarker guidelines (Lindeman et al., J Mol Diagn, 2018). This webinar, reviewing the evidence and logic behind the new recommendations, is designed for molecular pathologists, pathologists, oncologists, clinicians, trainees, and multidisciplinary tumor boards to help improve NSCLC patient care. Topics to be covered include recommendations regarding new predictive biomarkers; recommendations for testing for EGFR and ALK TKI resistance; and recommendations regarding new testing methodologies including the use of multiplexed genetic sequencing panels (e.g., NGS testing) to identify other treatment options beyond EGFR, ALK, and ROS1 as well as cell-free circulating DNA testing for EGFR resistance mutations. The revised 2018 CAP/IASLC/AMP lung cancer predictive biomarker guidelines will impact the daily practice of molecular pathologists and clinicians in the care of nearly 150,000 eligible lung cancer patients each year, regardless of whether in a community practice, a large reference lab, or an academic setting, and regardless of their level of expertise or experience.
- Review the new recommendations for lung cancer biomarker testing, their impact on patient care, and appropriate methods of testing (pre-analytic, analytic and post analytic actions).
- Evaluate how the evidence published since the original 2013 guideline have been impacted by new observations and evidence since the first guideline.
- Explain how molecular pathologists would utilize the recommendations in clinical practice using a case-based learning approach.
Recording Date: May 29, 2018
Duration: 1 hr
Level of Instruction: Basic
CE Credit has expired for this course.
This webinar is part 1 of a five-part series aimed at breaking down barriers to NSCLC testing and treatment.
For more information on this series, please go here.
Note: Join the AMP Family for discounted access to the most current educational resources!
All sales are final. No refunds will be issued.
No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.